论文部分内容阅读
Ever since cisplatin (cis-diamminedichloroplatinum(II)) was available for general oncology practice in 1978,platinum-based drugs have became one of the leading chemotherapeutic drugs in cancer treatment [1].?Dicycloplatin (cis-diammine(1,1-cyclobutane dicarboxylate) platinum(II):1,1 cyclobutane dicarboxylic acid complex,DCP) is a newly synthesized carboplatin (CBP) analogue showing higher solubility and stability over CBP in aqueous solution (Scheme 1) [2].It has been proved by pre-clinical research that it is superior compared to CBP against human prostatic and small cell lung cancer with reduced adverse effect (data unpublished).